Actively Recruiting
IMPACT COPD Cohort (China)
Led by Beijing Chao Yang Hospital · Updated on 2026-03-19
10000
Participants Needed
4
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic obstructive pulmonary disease (COPD) is a major chronic respiratory condition with high prevalence of multimorbidity. COPD and comorbidities interact dynamically, contributing to symptom fluctuation, acute exacerbations, hospitalization, and long-term disease progression. The IMPACT COPD Cohort (China) is a multicenter prospective observational cohort designed to establish a real-world evidence base for integrative Chinese-Western medicine management of COPD with comorbidities. The cohort integrates conventional clinical assessments (symptoms, questionnaires, spirometry, imaging, and biomarkers) with continuous multisensor digital monitoring (e.g., heart rate, blood pressure, activity, sleep patterns, and other physiological and behavioral measures) and digital Traditional Chinese Medicine (TCM) phenotyping (e.g., tongue, pulse, and facial diagnostics). The study aims to characterize risk profiles of high-risk populations and patients with confirmed comorbidities, develop and validate prediction models for comorbidity risk and acute exacerbation events, and support evidence generation for long-term management strategies with early screening and risk warning capabilities across hospital, community, and home settings.
CONDITIONS
Official Title
IMPACT COPD Cohort (China)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 40 and 80 years
- Diagnosis of chronic obstructive pulmonary disease (COPD) according to the 2025 GOLD criteria
You will not qualify if you...
- Acute exacerbation of COPD within the past 4 weeks
- Other lung diseases causing chronic respiratory failure, such as severe bronchiectasis, pneumoconiosis, post-tuberculosis destroyed lung, chest wall deformity, or neuromuscular disease
- Cystic fibrosis or interstitial lung disease
- Severe respiratory failure requiring long-term mechanical ventilation via tracheostomy
- History of lung or other organ transplantation
- Severe pleural disease or chest wall abnormalities interfering with imaging or lung function tests
- Lung cancer or other widespread metastatic malignancy
- Previous or current chemotherapy or radiotherapy affecting lung function or structure
- Uncontrolled rheumatic or autoimmune diseases like rheumatoid arthritis or systemic lupus erythematosus
- HIV infection
- Long-term use of immunosuppressive drugs or systemic corticosteroids
- Severe organ dysfunction such as severe heart, liver, kidney failure, or severe pulmonary arterial hypertension
- Hospitalization for myocardial infarction, heart failure, or other cardiovascular events within the past 3 months
- Major surgery involving chest, abdomen, or eyes within the past 3 months
- Intrathoracic metallic foreign bodies or implants interfering with imaging (e.g., pacemaker, defibrillator, metallic prosthetic valves, shrapnel)
- Allergy to any component of the Chinese herbal formula used in the study
- Allergy to any component of ICS+LABA+LAMA therapy or inhaler propellants/excipients
- Unable to accept or wear wearable devices
- Pregnant or breastfeeding women
- Long-term bedridden status, unable to perform daily activities, or life expectancy less than 1 year
- Dementia or cognitive impairment preventing consent and follow-up
- Living far from study center or planning to move within 3 years making follow-up impossible
- Current participation in another interventional clinical trial involving the respiratory system
- Refusal to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 4 locations
1
Hebi Coal Industry Group General Hospital
Hebi, Henan, China
Actively Recruiting
2
Tongliao Second People's Hospital
Tongliao, Neimeng, China
Actively Recruiting
3
Mianyang Third People's Hospital
Mianyang, Sichuan, China
Actively Recruiting
4
The First Affiliated Hospital of Shihezi University
Shihezi, Xinjiang, China
Actively Recruiting
Research Team
Z
Zujin Luo, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here